ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study

K. Shinoda1, H. Oguchi1, K. Nishikawa1, T. Yonekura1, M. Muramatsu1, T. Kawamura1, Y. Hamasaki1, T. Mikami2, K. Sakai1, S. Shishido1

1Toho University Faculty of Medicine, Tokyo, Japan, 2Pathology, Toho University Faculty of Medicine, Tokyo, Japan

Meeting: 2020 American Transplant Congress

Abstract number: B-076

Keywords: Kidney transplantation, Rejection

Session Information

Session Name: Poster Session B: Kidney Chronic Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The purpose of this study is to explore the risk factors associated with the development of chronic active antibody mediated rejection (CAAMR) after the kidney transplantation.

*Methods: The study cohort included 171 recipients who had been followed up over 1 year after the kidney transplantation among 269 recipients who underwent allograft biopsies between January 2016 and December 2017. The pathological diagnosis was performed according to the Banff 2013 criteria. The cohort included 21 patients who were diagnosed with pathological CAAMR, irrespective of the DSA presence, and 150 patients without any evidence of allograft rejection. We determined high- or low-dose of mycophenolate mofetil (MMF) by using the median dose as the cutoff (17.5 mg/kg/day).

*Results: The cohort was divided into two groups with or without diagnosis with CAAMR and evaluated the potential risk factors, including MMF dose (high vs low), duration after the transplantation, cyclosporine vs tacrolimus, past history of acute rejection, ABO incompatibility, the presence of preformed DSA (pDSA) (Table 1). The univariate analyses revealed that the low-dose of MMF and the presence of pDSA were significant risk factors (Chi square, p= 0.037 and p= 0.001, respectively). The duration after transplantation was significantly different between the groups. The multivariable logistic regression analysis revealed that low-dose MMF, pDSA, and duration after the kidney transplantation were independent risk factors for the development of pathological CAAMR (Odds ratio, 4.97 [95% CI: 1.09-22.68], 29.12 [95% CI: 4.62-183.5], 1.000696 [95% CI: 1.000378-1.001014], respectively) (Table 2).

*Conclusions: Low-dose MMF (< 17.5 mg/kg/day) as well as the presence of pDSA are significant risk factors for the development of CAAMR. Thus, caution is warranted against reducing the dose of MMF, especially in recipients with preformed DSA and longer follow-up period.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shinoda K, Oguchi H, Nishikawa K, Yonekura T, Muramatsu M, Kawamura T, Hamasaki Y, Mikami T, Sakai K, Shishido S. Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/reduced-dose-of-mycophenolate-mofetil-as-well-as-preformed-dsa-are-risk-factors-associated-with-the-development-of-chronic-active-antibody-mediated-rejection-after-kidney-transplantation-a-retrospect/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences